Market
Scenario
The increasing prevalence of chronic diseases such
as cancer, genetic diseases, and rare diseases, increase in adoption of genetic
testing, rising company initiatives, technological advancements, need for
efficient prenatal diagnosis, and increasing health awareness are estimated to
drive the market during the forecast period. However, factors such as expensive
tests, inaccuracy in results, and security concerns of the genes are estimated
to restrain the market growth during the forecast period.
Global
Gene Panel Market size is expected to register a CAGR of 12.16% to reach
USD 4,347.32 Million by 2025.
Segmentation
The global gene panel market is segmented on the
basis of product and service, technique, design, application, and end-user. The
gene panel market, by product and service, is segmented into test kits and
testing services. The global gene panel market by technique is segmented into
the amplicon-based approach and hybridization-based approach. The design
segment is segmented into predesigned gene panels and customized gene panels.
On the basis of application, the market is categorized into cancer risk
assessment, pharmacogenetics, diagnosis of congenital disorders, and other
applications. The cancer risk assessment segment is further sub-segmented into
syndrome-specific gene panels, high-penetrance gene panels, high and
moderate-penetrance gene panels, and comprehensive cancer risk panels. On the
basis of end-user, the market is categorized into hospitals, diagnostic
laboratories, research and academic institutes, and pharmaceutical and
biotechnology companies.
Key players
Some of the key players
for the global gene panel market are Thermo Fisher Scientific (US), F. Hoffmann-La
Roche AG (Switzerland), Illumina, Inc., BGI (China), Agilent Technologies
(US), Integrated DNA Technologies (IDT)
(US), Eurofins Scientific (US), QIAGEN (Germany), GENEWIZ, Novogene Corporation
(China), Personalis (US), GATC Biotech AG (GATC Biotech) (Germany), ArcherDx
(US), GeneDx., CENTOGENE AG, and others.
Regional Market Summary
The Americas dominates the global market for gene
panel. The increase in the patient pool for chronic diseases, government
initiatives for the development of cancer treatment, and presence of strong
market players such as Thermo Fisher Scientific drive the market growth in this
region. Europe (the U.K., Belgium, France, and the Netherlands) is second in
the market owing to the increasing research and development activities for
cancer and congenital diseases. Also, the high occurrence rate of cancer in
Europe influences the market growth in Europe. According to WHO, there are 3.7
million cases of cancer in Europe every year. Furthermore, Germany is predicted
to dominate the European market as there were 2, 24,089 number of deaths due to
cancer in 2014. Also, technological advancements coupled with an early
diagnosis of cancer is likely to drive market growth for gene panel in Germany.
Asia Pacific is expected to observe growth for the global gene panel market
owing to the growing prevalence of cancer and increasing health expenditure.
The Middle East and Africa with the presence of low-income countries, low
healthcare expenditures, and stringent government regulations accounted for the
least market share.
Browse More Life Sciences Reports
@ https://www.marketresearchfuture.com/categories/life-sciences-market-report
About US:
Market Research Future (MRFR), enable customers to
unravel the complexity of various industries through Cooked Research Report
(CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R),
Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact
Us:
Market
Research Future
Office
No. 528, Amanora Chambers
Magarpatta
Road, Hadapsar,
Pune
- 411028
Maharashtra,
India
Phone:
+1 646 845 9312
Email:
sales@marketresearchfuture.com
No comments:
Post a Comment